Advancements in technology, such as artificial intelligence and genomics, are transforming cancer research. AI algorithms can analyze vast datasets to identify potential drug candidates and predict patient responses. Genomic sequencing allows for the development of targeted therapies tailored to individual genetic profiles. Investors are increasingly focusing on tech-driven biotech companies that leverage these technologies to accelerate drug discovery and development.
